Tag: news

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Enigmatig Limited (NYSE American: EGG) (“Enigmatig” or the “Company”), a global business enabler empowering small and medium-sized enterprises (SMEs) to scale across borders, today rang the Closing Bell at the New York Stock Exchange (“NYSE”) to mark its recent listing and reaffirm its mission to power the global ambitions of bold, forward-thinking businesses.

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

PITTSBURGH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Langdon & Company, LLP (“Langdon & Company”) recently announced a cybersecurity incident, which impacted the personal information of forty-six thousand individuals connected to its client, Easterseals North Carolina and Virginia.¹ The information potentially impacted in the data breach includes individuals’ names, addresses, dates of birth, Taxpayer identification number, Social Security number, financial account information, medical information, health insurance information, and/or digital signature.

LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT

In today's rapidly evolving digital asset era, DIFD AUTO is leading the global cryptocurrency car buying revolution.

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the closing of its initial public offering of 1,250,000 Japanese common shares at a public offering price of US$4.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses payable by rYojbaba, was US$5 million. rYojbaba’s Japanese common shares began trading on the Nasdaq Capital Market on August 14, 2025, under the ticker symbol “RYOJ”.

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On August 14, 2025 the price of Hims & Hers Health (NYSE: HIMS) shares significantly dropped in after-hours trading after the financial press reported that the FTC is probing the company’s advertising practices and whether it makes it too difficult for customers to cancel subscriptions.